Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2022-07-21 00:00:00 ET · period of report 2022-07-19 · accession 0001567619-22-014299 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-07-21 | 2022-07-19 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | A - Grant | $0.00 | +40.0K | 305.9K | +15% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | S - Sale | $1.42 | -14.9K | 290.9K | -5% | -$21.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-19 | A | A | 40,000 | $0.00 | 305,853 | D | — | — | (F2) Includes 75,000 restricted stock units. |
| 2 | Common | Common Stock | 2022-07-20 | S | D | 14,911 | $1.42 | 290,942 | D | — | — | (F2) Includes 75,000 restricted stock units. |